| Literature DB >> 35455451 |
Abdel-Aziz Abu-Yamin1, Maisa Siddiq Abduh2,3, Sultan Ayesh Mohammed Saghir4, Naif Al-Gabri5,6.
Abstract
The thermal condensation of 3-(2-Furyl)acrolein with 2-Amino-6-ethoxybenzothiazole generated a new Schiff base, (1E,2E)-N-(6-ethoxybenzo[d]thiazol-2-yl)-3-(furan-2-yl)prop-2-en-1-imine (L), with general formula of C16H14N2O2S. Also, a series of lanthanide complexes of gadolinium, samarium, and neodymium (La-Lc) were synthesized utilizing acetonitrile as the solvent and triethylamine as a buffer and catalyst. Based on elemental analysis, mass spectroscopy, and FTIR analysis, all of the Bis-(1E,2E)-N-(6-ethoxybenzo[d]thiazol-2-yl)-3-(furan-2-yl)prop-2-en-1-iminetri-nitratolanthanide(III) complexes with the general formula [LnL2(NO3)3]·H2O are solids with a 2:1 molar ratio (ligand: metal). Based on conductivity estimates, they are nonelectrolytes and monoatomic paramagnetic according to the magnetic moment measurements, and one mole of lattice water was found after thermal gravimetric measurements and FTIR analysis. Therefore, the lanthanide complexes show a ten-coordination structure with a deformed bicapped square antiprismatic. The Schiff base and its complexes were screened for their antimicrobial, antifungal, antioxidant, and antitumor properties. Their antimicrobial and antifungal activities were strong, and they also produced good antioxidant and antitumor effects.Entities:
Keywords: 2-Amino-6-ethoxybenzothiazole; 3-(2-Furyl)acrolein; antimicrobial; antioxidant; antitumor; lanthanide complexes; spectroscopic; synthesis
Year: 2022 PMID: 35455451 PMCID: PMC9027428 DOI: 10.3390/ph15040454
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Scheme 1Synthesis of Schiff base L and its LnIII complexes (La–Lc).
Peak assignment in FTIR spectra (cm−1) of L, La, Lb, and Lc.
| Compounds | υ(HC=N) Imine | γ(HC=N) Imine | υ(C=N) | C-S-C Thiazole | C-O | υH2O | υ(Ln-S) | υ(Ln-N) |
|---|---|---|---|---|---|---|---|---|
|
| 1660 | 1016 | 1603 | 758 | 1057 | - | - | - |
|
| 1642 | 1045 | 1601 | 804 | 1060 | 3450 | 416 | 547 |
|
| 1646 | 1044 | 1601 | 805 | 1060 | 3477 | 428 | 563 |
|
| 1645 | 1034 | 1599 | 815 | 1060 | 3465 | 421 | 558 |
Figure 1UV–visible spectra of concentrated DMF solution of Lc.
Physicochemical properties of synthesized compounds.
| Compound | Molecular Formula Molar Mass g Mol−1 ( | Yield | m. p. | μeff | Λm: Molar Conductance S.L/mol | Elemental Analysis: | |||
|---|---|---|---|---|---|---|---|---|---|
| C (%) | H (%) | N (%) | S (%) | ||||||
|
|
| 0.92 g | 145–146 | - | - | 64.41 | 4.73 | 9.39 | 10.75 |
|
|
| 0.70 g | 195–196 | 7.90 | 23 | 40.12 | 3.16 | 10.23 | 6.69 |
|
|
| 0.72 g | 210–211 | 1.88 | 25 | 40.41 | 3.18 | 10.31 | 6.74 |
|
|
| 0.65 g | 224–225 | 3.24 | 28 | 40.67 | 3.20 | 10.38 | 6.79 |
Figure 2TGA thermograms of the three complexes: La, Lb, and Lc.
Total antioxidant activity and DPPH radical scavenging activity of the Schiff base compound and its complexes.
| Sample Code | TAC | DPPH |
|---|---|---|
|
| 25.97 ± 2.38 | 478.52 ± 13.84 |
|
| 18.71 ± 3.41 | 570.16 ± 14.08 |
|
| 17.04 ± 1.91 | 505.82 ± 11.76 |
|
| 28.85 ± 3.32 | 410.18 ± 15.34 |
|
| 66.08 ± 1.18 | 10.56 ± 0.78 |
|
| 71.82 ± 1.76 | 5.78 ± 0.27 |
BHT—butyl hydroxytoluene.
Minimum inhibitory concentration in mm ± SD of Schiff base compound and its complexes.
| Sample | Diameter of Inhibition Zones (mm) | ||||
|---|---|---|---|---|---|
| L | La | Lb | Lc | Control | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
|
|
| ||||
|
| 22.20 ± 0.56 | 17.01 ± 0.02 | 19.00 ± 0.30 | 23.13 ± 0.31 | 17.01 ± 0.02 |
|
| 20.10 ± 0.40 | 20.03 ± 0.04 | 17.97 ± 0.35 | 18.78 ± 0.36 | 20.03 ± 0.04 |
|
|
| ||||
|
| 15.17 ± 0.55 | 24.01 ± 0.01 | 14.20 ± 0.36 | 18.07 ± 0.35 | 24.01 ± 0.01 |
|
| 20.10 ± 0.36 | 26.02 ± 0.03 | 18.10 ± 0.30 | 20.80 ± 0.52 | 26.02 ± 0.03 |
|
|
| ||||
|
| 18.17 ± 0.40 | 29.90 ± 0.01 | 17.10 ± 0.36 | 22.60 ± 0.40 | 29.90 ± 0.01 |
|
| 16.97 ± 0.42 | 25.00 ± 0.01 | 14.00 ± 0.26 | 18.60 ± 0.26 | 25.00 ± 0.01 |
The inhibitory effects (IC50%) of the Schiff base compound and its complexes against different types of cell lines.
| Compound L | Compound La | Compound Lb | Compound Lc | ||||
|---|---|---|---|---|---|---|---|
|
| 41.19 ± 6.70 |
| 164.72 ± 9.66 |
| 50.21 ± 5.03 |
| 42.18 ± 5.56 |
|
| 84.90 ± 6.98 |
| 106.31 ± 5.97 |
| 40.15 ± 0.31 |
| 55.42 ± 3.60 |
|
| 58.81 ± 2.53 |
| 83.28 ± 2.36 |
| 82.52 ± 10.16 |
| 105.23 ± 11.49 |
|
| >500 |
| >500 |
| >500 |
| >500 |
HepG-2: human hepatocellular carcinoma, MCF-7: human breast cancer cell line, PC-3: prostate carcinoma, WISH: human amnion (normal liver cells), Huh-7: human hepatocellular cancer cell line, MDA-MB231: human breast carcinoma, A-549: lung carcinoma, MRC-5: normal human lung fibroblast, HCT-116: human colon carcinoma, CACO2: human lung fibroblast normal cell line, RD: human muscle Rhabdomyosarcoma cell, WI-38: human lung fibroblast normal cells, HEP-2: larynx carcinoma cells, HFB4: human normal melanocytes.